Search | IOVS | ARVO Journals

Showing 1 – 20 of 40

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

ophthafutur ® safelight as a transscleral illumination device for vitreoretinal surgeries

Frank H J Koch; Christina Sebode; Claudia Frank; Andreas Hofmann; Tessa Kustermann; Svenja Deuchler

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):4441.

ARVO Annual Meeting Abstract June 2024

Comparison of simulator-based versus traditional training of fundus biomicroscopy for medical students in a prospective, randomized trial

Svenja Deuchler; Yaser Abu-Dail; Tim Berger; Albéric Sneyers; Frank H J Koch; Claudia Buedel; Hanns Ackermann; Elias Flockerzi; Berthold Seitz

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):4426.

ARVO Annual Meeting Abstract June 2023

The Eyesi Slit Simulator as a training option for medical students: results of a prospective, exploratory study

Svenja Deuchler; Yaser Abu Dail; Frank H J Koch; Claudia Buedel; Hanns Ackermann; Elias Flockerzi; Berthold Seitz

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):4998.

ARVO Annual Meeting Abstract June 2022

Virtual reality microsurgery training during medical school: data from implementation of Eyesi Surgical in ophthalmology clerkship in Germany

Svenja Deuchler; Julia Scholtz; Hanns Ackermann; Frank Koch

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3413 – F0313.

ARVO Annual Meeting Abstract June 2022

The use of hypersonic vitrectomy as a novel approach for retinal reattachment surgery

Frank H J Koch; Julia Scholtz; Timo Knoch; Svenja Deuchler

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3414 – F0314.

ARVO Annual Meeting Abstract June 2021

Intraocular illumination – opportunities and risks of novel approaches

Frank H J Koch; Svenja Deuchler; Christian Lingenfelder; Phillip koelbl; Nicole Siebert; Robin Haag; Denise Sinning; Pankaj Singh; Thomas Kohnen; Martin hessling

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):3621.

ARVO Annual Meeting Abstract June 2021

Efficiency of simulation in combination with independent online learning within the framework of "EyesiNet" in ophthalmology education

Svenja Deuchler; Christina Sebode; Hanns Ackermann; Ingo Schmack; Pankaj Singh; Thomas Kohnen; Frank H J Koch

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):3620.

ARVO Annual Meeting Abstract June 2020

The impact of changes at the vireoretinal interface and retinal thickness following the administration of a single 0.19 mg fluocinolone acetonide (FAc, ILUVIEN) device, implanted after partial PPV in patients with persistent or recurrent DME – results from the ILUVIT study, a single center, phase IV study.

Frank H J Koch; Pankaj Singh; Adonis Chedid; Natallia Brui; Thomas Kohnen; Hanns Ackermann; Svenja Deuchler

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4870.

ARVO Annual Meeting Abstract June 2020

Reduced vitreous cytokine levels following the administration of a single 0.19 mg fluocinolone acetonide (FAc, ILUVIEN) implant in patients with persistent or recurrent DME – results from the ILUVIT study.

Svenja Deuchler; Pankaj Singh; Adonis Chedid; Natallia Brui; Thomas Kohnen; Hanns Ackermann; Frank H J Koch

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4873.

ARVO Annual Meeting Abstract June 2020

The correlation between the expression of cytokines and growth factors and the clinical stage of diabetic retinopathy in patients with DME – results from the ILUVIT study, a single center, phase IV study.

Pankaj Singh; Svenja Deuchler; Adonis Chedid; Natallia Brui; Thomas Kohnen; Hanns Ackermann; Frank H J Koch

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4879.

ARVO Annual Meeting Abstract June 2020

Real-life long-term outcomes for patients treated with the 0.19 mg fluocinolone acetonide (FAc; ILUVIEN) intravitreal implant for DME: Three-year follow-up from the RegIstry Safety Study (IRISS) .

Ramin Khoramnia; Frank H J Koch; Usha Chakravarthy; Simon R Taylor; Joao Paulo Castro de Sousa; Clare Bailey

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4862.

ARVO Annual Meeting Abstract July 2019

Interim results from the prospective IDEAL registry study – treatment outcomes achieved with the intravitreal 0.19 mg fluocinolone acetonide implant in German clinical practices.

Ramin Khoramnia; Frank Koch; Gerd U. Auffarth

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):2619.

ARVO Annual Meeting Abstract July 2019

Real-world outcomes from the 3-year European ILUVIEN (0.19 mg fluocinolone acetonide implant) RegIstry Safety Study (IRISS)

Frank HJ Koch; Usha Chakravarthy; Ramin Khoramnia; Simon Taylor; Clare Bailey; João Sousa

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):2622.

ARVO Annual Meeting Abstract July 2019

Earlier intervention is associated with improved visual outcomes in patients with persistent or recurrent diabetic edema - Clinical insights from the ILUVIEN (fluocinolone acetonide) Registry Safety Study (IRISS)

Panos Vouzounis; Simon Taylor; Usha Chakravarthy; Clare Bailey; Frank HJ Koch; João Sousa

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):2630.

ARVO Annual Meeting Abstract June 2017

Efficacy and safety outcomes following the use of ILUVIEN in vitrectomized eyes – results from the University Eye Clinic Frankfurt in Germany

Frank H J Koch; Pankaj Singh; Adonis Chedid; Michael Mueller; Thomas Kohnen; Svenja K Deuchler

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2794.

ARVO Annual Meeting Abstract June 2017

Important issues to reduce the retinal redetachment rate after vitrectomy with temporary silicone oil tamponade

Svenja Deuchler; Pankaj Singh; Michael Mueller; Thomas Kohnen; Clemens Wagner; Markus Schill; hanns Ackermann; Joerg Iwanczuk; Frank H J Koch

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2813.

ARVO Annual Meeting Abstract June 2017

The use of intravitreal implant ILUVIEN ® (fluocinolone acetonide) after prior OZURDEX ® Implant (DEX) (Dexamathason) in patients with diabetic macular edema (DME) - Efficacy and safety outcomes from the University Eye Clinic in Frankfurt, Germany

Pankaj Singh; Adonis Chedid; Svenja Deuchler; Thomas Kohnen; Michael Mueller; Frank H J Koch

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2818.

ARVO Annual Meeting Abstract September 2016

Simulated vitreoretinal surgery to prepare for real surgery

Frank H J Koch; Clemens Wagner; Pankaj Singh; Michael Mueller; Rachid Benjilali; Markus Schill; Hanns Ackermann; Dimitra Bon; Benjamin Schoene; Michael Koss; Svenja Deuchler

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):1076.

ARVO Annual Meeting Abstract September 2016

Interaction between lens transparency loss and retinal reattachment surgery with preliminary silicone oil fill

Svenja Deuchler; Pankaj Singh; Michael Mueller; Thomas Kohnen; Hanns Ackermann; Joerg Iwanczuk; Rachid Benjilali; Frank H J Koch

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):1078.

ARVO Annual Meeting Abstract September 2016

Chromovitrectomy with Vitreodyne™.

Pankaj Singh; Svenja Deuchler; Michael Mueller; Thomas Kohnen; Diego Sousa-Martins; Beatriz Pinheiro-Torres; Frank H J Koch

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):4452.

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

ophthafutur ® safelight as a transscleral illumination device for vitreoretinal surgeries

Comparison of simulator-based versus traditional training of fundus biomicroscopy for medical students in a prospective, randomized trial

The Eyesi Slit Simulator as a training option for medical students: results of a prospective, exploratory study

Virtual reality microsurgery training during medical school: data from implementation of Eyesi Surgical in ophthalmology clerkship in Germany

The use of hypersonic vitrectomy as a novel approach for retinal reattachment surgery

Intraocular illumination – opportunities and risks of novel approaches

Efficiency of simulation in combination with independent online learning within the framework of "EyesiNet" in ophthalmology education

Reduced vitreous cytokine levels following the administration of a single 0.19 mg fluocinolone acetonide (FAc, ILUVIEN) implant in patients with persistent or recurrent DME – results from the ILUVIT study.

The correlation between the expression of cytokines and growth factors and the clinical stage of diabetic retinopathy in patients with DME – results from the ILUVIT study, a single center, phase IV study.

Real-life long-term outcomes for patients treated with the 0.19 mg fluocinolone acetonide (FAc; ILUVIEN) intravitreal implant for DME: Three-year follow-up from the RegIstry Safety Study (IRISS) .

Interim results from the prospective IDEAL registry study – treatment outcomes achieved with the intravitreal 0.19 mg fluocinolone acetonide implant in German clinical practices.

Real-world outcomes from the 3-year European ILUVIEN (0.19 mg fluocinolone acetonide implant) RegIstry Safety Study (IRISS)

Earlier intervention is associated with improved visual outcomes in patients with persistent or recurrent diabetic edema - Clinical insights from the ILUVIEN (fluocinolone acetonide) Registry Safety Study (IRISS)

Efficacy and safety outcomes following the use of ILUVIEN in vitrectomized eyes – results from the University Eye Clinic Frankfurt in Germany

Important issues to reduce the retinal redetachment rate after vitrectomy with temporary silicone oil tamponade

The use of intravitreal implant ILUVIEN ® (fluocinolone acetonide) after prior OZURDEX ® Implant (DEX) (Dexamathason) in patients with diabetic macular edema (DME) - Efficacy and safety outcomes from the University Eye Clinic in Frankfurt, Germany

Simulated vitreoretinal surgery to prepare for real surgery

Interaction between lens transparency loss and retinal reattachment surgery with preliminary silicone oil fill

Chromovitrectomy with Vitreodyne™.

To View More...

You must be signed into an individual account to use this feature.